Ito Hideyuki, Fujita Hiroki, Takahashi Takamune
Vanderbilt University Medical Center, Division of Nephrology and Hypertension, S-3223, MCN, Nashville, TN 37232, USA +1 615 343 4312 ; +1 615 343 7156 ;
Expert Opin Med Diagn. 2008 Feb;2(2):161-9. doi: 10.1517/17530059.2.2.161.
Clinical management and therapeutic intervention from the earlier stage of diabetic nephropathy (DN) is of major importance to prevent the progression of DN to end stage renal disease. At present, the measurement of albuminuria is used as a standardized non-invasive test for the diagnosis of early DN. Diabetic kidney disease, however, is not detected by this test in some cases. Hence, efforts have been made to find better diagnostic biomarkers of DN. These investigations have identified several proteins that can be used as diagnostic biomarkers of DN, including urinary immunoglobulin G, transferrin, ceruloplasmin and serum cystatin-C. Further, recent proteomics approaches have isolated potential biomarkers of DN. This review summarizes the diagnostic biomarkers developed over the last decade, and comments on their impacts in the diagnosis and management of this disease.
糖尿病肾病（DN）早期的临床管理和治疗干预对于预防DN进展至终末期肾病至关重要。目前，蛋白尿测量被用作早期DN诊断的标准化非侵入性检测方法。然而，在某些情况下，该检测无法检测出糖尿病肾病。因此，人们一直在努力寻找更好的DN诊断生物标志物。这些研究已经确定了几种可作为DN诊断生物标志物的蛋白质，包括尿免疫球蛋白G、转铁蛋白、铜蓝蛋白和血清胱抑素C。此外，最近的蛋白质组学方法已经分离出DN的潜在生物标志物。本综述总结了过去十年中开发的诊断生物标志物，并对它们在该疾病诊断和管理中的影响进行了评论。
